; The mission of the MSCP SPORE Career Development Program (CDP) is to stimulate basic, translational, and clinical research by recruiting and supporting new investigators in the area of melanoma and other skin cancers. The CDP provides financial resources for this mission, while the SPORE itself provides a supportive and stimulating research environment. In the previous MSCP SPORE grant period, we supported 7 CDP awardees, all but one of whom were eariy-stage investigators (one Research Associate, one Research Instructor, and four Assistant or Research Assistant Professors);5 of our 7 CDP awardees were women. All CDP Awardees have experienced success in advancing their careers, publishing their work, and obtaining extramural funding. We will continue to solicit proposals twice per year and to use a peer-reviewed scoring system to prioritize proposals for funding. The CDP Co-Directors, Executive Committee, and Internal and External Advisory Board members participate in the review process, together with the Patient Advocates and additional experts who may be called upon if special reviewer expertise is necessary. The CDP will track progress of the successful applications and provide advisors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A;Biospecimen Core B;Biostatistics Core C;and Informatics Core D) and that they are integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of support to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether CDP projects are found to merit promotion to full SPORE projects. Awardees will also be advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to Core resources to aid in this endeavor.

Public Health Relevance

The MSCP SPORE will identify and support investigators new to research in melanoma and skin cancer with both pilot study funding and expertise and assistance in planning and preparing grant applications for independent funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-07
Application #
8933155
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
2006-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
$65,623
Indirect Cost
$23,382
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Hoot, Joyce W; Wang, Li; Kho, Terry et al. (2018) The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatolog Treat 29:272-276
Anderson, Alyce J M; Ferris, Laura K; Binion, David G et al. (2018) Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci 63:2564-2572
Geskin, Larisa J; Damiano, James J; Patrone, Christina C et al. (2018) Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res 28:211-221
Geskin, Larisa J; Akilov, Oleg E; Kwon, Soonyou et al. (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67:423-434
Davar, Diwakar; Wang, Hong; Chauvin, Joe-Marc et al. (2018) Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol :JCO1800632

Showing the most recent 10 out of 209 publications